deltatrials
Completed PHASE2 INTERVENTIONAL 1-arm NCT02292186

A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis

A Phase 2, Open-label Extension Study to Evaluate the Long-Term Safety, Clinical Activity, and Pharmacokinetics of ALN-TTRSC in Patients With Transthyretin (TTR) Cardiac Amyloidosis Who Have Previously Received ALN-TTRSC

Sponsor: Alnylam Pharmaceuticals

Conditions TTR-mediated Amyloidosis
Interventions Revusiran (ALN-TTRSC)
Updated 14 times since 2017 Last updated: Jul 7, 2020 Started: Oct 31, 2014 Primary completion: Feb 22, 2017 Completion: Feb 22, 2017
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates TTR-mediated Amyloidosis and is currently completed. Alnylam Pharmaceuticals leads this study, which shows 14 recorded versions since 2014 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Jun 2018 · 12 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Aug 2018 · 31 days · monthly snapshot~Aug 2018 – ~Mar 2020 · 19 months · monthly snapshot~Mar 2020 – ~Aug 2020 · 5 months · monthly snapshot~Aug 2020 – ~Jan 2021 · 5 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Dec 2022 · 12 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

14 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Jan 2023 — Jul 2024 [monthly]

    Completed PHASE2

  4. Dec 2022 — Jan 2023 [monthly]

    Completed PHASE2

  5. Dec 2021 — Dec 2022 [monthly]

    Completed PHASE2

▶ Show 9 earlier versions

  1. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE2

  2. Aug 2020 — Jan 2021 [monthly]

    Completed PHASE2

  3. Mar 2020 — Aug 2020 [monthly]

    Completed PHASE2

  4. Aug 2018 — Mar 2020 [monthly]

    Completed PHASE2

  5. Jul 2018 — Aug 2018 [monthly]

    Completed PHASE2

  6. Jun 2018 — Jul 2018 [monthly]

    Completed PHASE2

  7. Jun 2017 — Jun 2018 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  8. Feb 2017 — Jun 2017 [monthly]

    Active Not Recruiting PHASE2

  9. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE2

    First recorded

Oct 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Alnylam Pharmaceuticals
Data source: Alnylam Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations